HiberCell, Inc.

A clinical-stage oncology company focused on developing first-in-class therapies that target adaptive-stress driven vulnerabilities. HiberCell aims to combat treatment resistance, cancer relapse, and metastasis by modulating adaptive stress pathways and enhancing anti-tumor immunity, differentiating itself through its unique approach to cancer treatment. The primary beneficiaries of HiberCell's innovations are cancer patients who face challenges with treatment resistance and disease recurrence.